GLP-1

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New Zealand dairy giant Fonterra is moving to serve the nutritional needs of people taking weight-loss medications such as GLP-1 drugs, which reduce appetite and can leave users short of protein and key nutrients. The company is positioning high-protein dairy products to fill that gap, tapping into one of the fastest-growing trends in global food and health.

Plug & Play, the innovation platform, is turning its attention to companion nutrition for people taking GLP-1 weight-loss drugs, framing it as the next growth area for the microbiome and nutrition sector. As uptake of medications like Ozempic and Wegovy grows, attention is shifting to foods and supplements that help patients maintain muscle, gut health and nutrient intake while eating less.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.

A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.

Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being described as changing more than obesity treatment, with new discussion of their effects on mental health. The Atlantic examines how these medications may influence mood, addiction and behavior, suggesting the story of weight loss medicine is expanding into psychiatry and brain science.

Supplement company Smidge has introduced a GLP-1 companion bundle aimed at supporting digestion and nutrient intake for people taking GLP-1 medications, which are known to affect appetite and gut function. The bundle is positioned as a nutritional support product for users of these weight-loss and diabetes drugs.

A health news roundup covers four topics: cychlorphine, a substance drawing attention for potential effects on testosterone levels; possible links between GLP-1 weight-loss and diabetes drugs and vision loss; and an ongoing salmonella outbreak tied to jalapeño peppers. Together the items touch on medication safety, supplement trends and a foodborne illness investigation that health officials are monitoring.

Supplement brand Smidge has introduced a nutrition bundle combining five supplements into a single daily routine, aimed at people taking GLP-1 weight-loss medications. The concept targets nutritional gaps reported by users of drugs like Ozempic and Wegovy, who often eat less and may miss key nutrients. It reflects a broader wave of products being marketed to the fast-growing GLP-1 user base.

A new obesity drug has been described as the most powerful yet after trial participants reportedly lost up to 25% of their body weight. The results, reported by Ars Technica, would surpass figures associated with current GLP-1 medications such as Wegovy and Zepbound, intensifying competition among drugmakers in the fast-growing weight-loss treatment market.

New research indicates that close to one in six children taking GLP-1 medications, widely used for weight management and diabetes, develop nutritional deficiencies. The finding raises questions about monitoring and dietary support for young patients on these increasingly prescribed drugs, as clinicians weigh the benefits of treatment against risks of inadequate nutrient intake during childhood development.

Supplement company Smidge has introduced a GLP-1 Companion Bundle aimed at people taking GLP-1 weight-loss medications, combining products intended to support digestive wellness and whole-food nutrition. The announcement was carried on Yahoo Finance. The company positions the bundle as a way to address nutritional gaps and digestive discomfort that can accompany GLP-1 drug use.

A new report finds that 12.4% of teenagers taking GLP-1 weight-loss and diabetes medications are diagnosed with vitamin D deficiency within a year, and few of them receive nutrition counseling to offset the risk. The findings raise concerns about whether young patients on these increasingly prescribed drugs are getting adequate dietary support alongside treatment.

A new wave of obesity medicines is being discussed as the field looks beyond the established GLP-1 drugs semaglutide and tirzepatide. Coverage highlights emerging treatments in development that could expand options for patients and clinicians treating obesity, a category that has drawn enormous attention since GLP-1 therapies reshaped weight-loss care. Details on specific drug candidates remain limited.